Krystal Biotech, Inc. (NASDAQ:KRYS) Shares Purchased by Creative Planning

Creative Planning boosted its holdings in Krystal Biotech, Inc. (NASDAQ:KRYS) by 21.6% during the second quarter, Holdings Channel reports. The institutional investor owned 3,484 shares of the company’s stock after buying an additional 618 shares during the period. Creative Planning’s holdings in Krystal Biotech were worth $640,000 at the end of the most recent quarter.

Other hedge funds and other institutional investors also recently added to or reduced their stakes in the company. Vanguard Group Inc. raised its position in shares of Krystal Biotech by 1.5% in the 4th quarter. Vanguard Group Inc. now owns 2,435,774 shares of the company’s stock worth $302,182,000 after buying an additional 35,632 shares during the period. Price T Rowe Associates Inc. MD increased its stake in Krystal Biotech by 54.1% during the first quarter. Price T Rowe Associates Inc. MD now owns 658,618 shares of the company’s stock worth $117,189,000 after acquiring an additional 231,255 shares during the last quarter. Dimensional Fund Advisors LP raised its holdings in shares of Krystal Biotech by 1.3% in the 2nd quarter. Dimensional Fund Advisors LP now owns 580,452 shares of the company’s stock worth $106,593,000 after purchasing an additional 7,537 shares during the period. Hood River Capital Management LLC lifted its stake in shares of Krystal Biotech by 5.1% in the 2nd quarter. Hood River Capital Management LLC now owns 521,093 shares of the company’s stock valued at $95,694,000 after purchasing an additional 25,507 shares in the last quarter. Finally, Goldman Sachs Group Inc. increased its position in Krystal Biotech by 23.7% during the 4th quarter. Goldman Sachs Group Inc. now owns 228,053 shares of the company’s stock worth $28,292,000 after purchasing an additional 43,709 shares in the last quarter. Hedge funds and other institutional investors own 86.29% of the company’s stock.

Insider Activity at Krystal Biotech

In other Krystal Biotech news, insider Suma Krishnan sold 25,000 shares of the firm’s stock in a transaction on Thursday, September 12th. The shares were sold at an average price of $197.76, for a total transaction of $4,944,000.00. Following the completion of the transaction, the insider now directly owns 1,500,882 shares of the company’s stock, valued at $296,814,424.32. This trade represents a 0.00 % decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website. 14.10% of the stock is currently owned by corporate insiders.

Krystal Biotech Stock Performance

NASDAQ:KRYS opened at $178.71 on Monday. The stock has a market cap of $5.10 billion, a price-to-earnings ratio of 95.57 and a beta of 0.82. Krystal Biotech, Inc. has a one year low of $93.95 and a one year high of $219.34. The business’s 50-day simple moving average is $186.77 and its 200 day simple moving average is $180.05.

Krystal Biotech (NASDAQ:KRYS) last announced its earnings results on Monday, August 5th. The company reported $0.53 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $0.50 by $0.03. The company had revenue of $70.28 million for the quarter, compared to analyst estimates of $65.27 million. Krystal Biotech had a return on equity of 1.99% and a net margin of 63.73%. Krystal Biotech’s quarterly revenue was up 70283900.0% on a year-over-year basis. During the same period in the prior year, the company posted ($1.25) EPS. On average, equities research analysts predict that Krystal Biotech, Inc. will post 3.13 EPS for the current year.

Analyst Upgrades and Downgrades

A number of research analysts have weighed in on the stock. Chardan Capital lifted their price target on shares of Krystal Biotech from $153.00 to $208.00 and gave the company a “buy” rating in a research report on Monday, August 5th. HC Wainwright upped their price target on shares of Krystal Biotech from $200.00 to $221.00 and gave the stock a “buy” rating in a research report on Wednesday, August 28th. Citigroup reissued a “neutral” rating and issued a $204.00 price objective (up from $195.00) on shares of Krystal Biotech in a research report on Tuesday, August 6th. William Blair upgraded Krystal Biotech to a “strong-buy” rating in a research note on Friday, August 30th. Finally, Cantor Fitzgerald reiterated an “overweight” rating on shares of Krystal Biotech in a research note on Thursday, August 29th. One equities research analyst has rated the stock with a hold rating, seven have issued a buy rating and one has assigned a strong buy rating to the stock. According to MarketBeat.com, the company currently has a consensus rating of “Buy” and an average price target of $196.75.

About Krystal Biotech

Krystal Biotech, Inc, a commercial-stage biotechnology company, discovers, develops, and commercializes genetic medicines for patients with rare diseases in the United States. It commercializes VYJUVEK (beremagene geperpavec-svdt, or B-VEC) for the treatment of dystrophic epidermolysis bullosa (DEB).